The neuronal guidance protein netrin-1 reduces alveolar inflammation in a porcine model of acute lung injury by Mutz, Christian et al.
RESEARCH Open Access
The neuronal guidance protein netrin-1 reduces
alveolar inflammation in a porcine model of
acute lung injury
Christian Mutz
1†, Valbona Mirakaj
2,3†, Dierk A Vagts
1, Phillipp Westermann
1, Kristina Waibler
1, Klemens König
2,
Thomas Iber
1,3, Gabriele Nöldge-Schomburg
1, Peter Rosenberger
2,3*
Abstract
Introduction: Acute lung injury (ALI) is an inflammatory disorder of pulmonary or extrapulmonary origin. We have
previously demonstrated that netrin-1 dampens murine ALI, and in an attempt to advance this finding into future
clinical practice we evaluated whether netrin-1 would reduce alveolar inflammation during porcine ALI.
Methods: This was a controlled in vivo experimental study in pigs. We induced ALI through lipoploysaccharide
(LPS) infusion (50 μg/kg) for 2 hours. Following this, we exposed animals to either vehicle, intravenous netrin-1
(netrin-1 i.v.) or inhaled netrin-1 (netrin-1 inh.). Serum samples and bronchoalveolar lavage (BAL) were obtained to
determine levels of tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, interleukin-6 and interleukin-8 at baseline
and 6 hours following treatment. Myeloperoxidase activity (MPO) and protein levels were determined in the BAL,
and tissue samples were obtained for histological evaluation. Finally, animals were scanned with spiral CT.
Results: Following LPS infusion, animals developed acute pulmonary injury. Serum levels of TNF-a and IL-6 were
significantly reduced in the netrin-1 i.v. group. BAL demonstrated significantly reduced cytokine levels 6 hours
post-netrin-1 treatment (TNF-a: vehicle 633 ± 172 pg/ml, netrin-1 i.v. 84 ± 5 pg/ml, netrin-1 inh. 168 ± 74 pg/ml;
both P < 0.05). MPO activity and protein content were significantly reduced in BAL samples from netrin-1-treated
animals. Histological sections confirmed reduced inflammatory changes in the netrin-1-treated animals. Computed
tomography corroborated reduced pulmonary damage in both netrin-1-treated groups.
Conclusions: We conclude that treatment with the endogenous anti-inflammatory protein netrin-1 reduces
pulmonary inflammation during the initial stages of ALI and should be pursued as a future therapeutic option.
Introduction
Acute lung injury (ALI) is a devastating disorder of the
lung with an incidence of approximately 17.5/100,000
per year and is associated with high mortality [1,2]. The
hallmarks of ALI include the disruption of the alveolar-
capillary barrier, the extravasation of fluid from the
vascular space causing pulmonary edema and the infil-
tration of leukocytes into the alveolar space [3,4]. Oxy-
genation is impaired, and the acute respiratory distress
syndrome (ARDS) develops when the oxygenation index
deteriorates to a PaO2/FiO2 quotient below 200 [2]. The
importance of these inflammatory changes for the
pathophysiology of ALI is supported by the finding that
experimental lung injury can be substantially reduced
through the depletion of neutrophils [5]. During the
initial stages of ALI, neutrophils migrate into the alveo-
lar space in response to secreted cytokines. Furthermore,
cytokines increase the activation of alveolar macro-
phages and aggravate the intra-alveolar inflammation
that might become self-propagating within the pulmon-
ary tissue [5,6]. Several investigators have described the
importance of this process by identifying a correlation
between alveolar cytokine levels and the severity of pul-
monary organ injury [7-11]. As a result, pulmonary oxy-
gen exchange is compromised [12,13]. Strategies for the
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function through reducing the extent of pulmonary
inflammation [14,15].
Netrin-1 was initially described in the context of central
nervous system (CNS) development, where it influences
axonal migration and guides CNS development [16-18].
B u tn e t r i n - 1i sa l s oe x p r e s s e do u t s i d et h eC N Si nt h e
intestine, kidney and lung, where it controls the trafficking
of leukocytes from the vascular space [19,20]. During peri-
ods of intestinal hypoxia, netrin-1 is induced through
hypoxia inducible factor 1-a and dampens local inflamma-
tion of the large intestinal surface [21]. This is in large
part dependent on the coexpression of the adenosine 2B
receptor (A2BAR), a receptor that is transcriptionally
induced during hypoxia and inflammation [22,23]. Simi-
larly to the intestinal organs, the pulmonary surface is
composed of a large mucosal lining. This mucosal surface
of the lung is characterized by a close proximity of the vas-
cular and the alveolar space building the alveolar-capillary
barrier. We were recently able to demonstrate that netrin-
1 is expressed in endothelial and epithelial cells within pul-
monary tissue and is significantly repressed during inflam-
matory and mechanical lung injury. Furthermore,
employing animals with endogenous repression of netrin-
1, we demonstrated increased pulmonary damage in these
animals compared to littermate controls and that a substi-
tution with exogenous netrin-1 resulted in a significant
reduction of lung injury [20]. The protective role of
netrin-1 in our murine model was also dependent on the
A2BAR corroborating the protective potential of the
A2BAR during lung injury [23].
Given the anti-inflammatory potential of neuronal gui-
dance protein netrin-1 and the important role of a con-
trol of pulmonary inflammation during ALI, we
investigated whether our previous findings could be
translated further and attempted to bring netrin-1 one
step forward to a potential clinical use. For this purpose,
we decided to use systemic and local netrin-1 adminis-
tration to find the potentially best application for future
therapeutic evaluation. We hypothesized that netrin-1
might be able to influence the extent of pulmonary
inflammation and leukocyte activity within the alveolar
space in a large animal model of ALI. This study was
therefore aimed at improving our understanding of
netrin-1 for a possible translation from mice to humans.
Materials and methods
Research animals
The study was approved by the local Ethics Committee
on Animal Research (Landesamt für Landwirtschaft
Rostock, Approval LALLF M-V/TSD/7221.3-1.1-038/08)
and in concordance with the Helsinki convention. Female
domestic pigs with an age of 3-4 months were used for
the experimental procedure. The average weight of ani-
mals used in each group is provided in Table 1.
Anesthesia
Animals were premedicated with 8 μgk g
-1 intramuscu-
lar (i.m.) azaperone (Janssen-Cilag, Neuss, Germany), 6.0
mg kg
-1 ketamine (Bela-Pharm, Vechta, Germany) and
0.25 mg kg
-1 midazolam (Merckle, Blaubeuren, Ger-
many) after overnight fasting and receiving water ad
libitum. After an intravenous line was placed, anesthesia
was induced intravenously (i.v.) with 3 μgk g
-1 fentanyl
(Janssen-Cilag, Neuss, Germany), 1.6 mg kg
-1 ketamine
(DeltaSelect, Pfullingen, Germany), 0.3 μgk g
-1 flunitra-
zepam (Roche Pharma, Grenzach, Germany) and 0.3 mg
kg
-1 pancuronium (Hikma Farmaceutica, Reute, Ger-
many). The trachea was intubated and anesthesia main-
tained by continuous i.v. infusion of flunitrazepam 85 μg
kg
-1 h
-1, 0.2 mg kg
-1 h
-1 pancuronium and 7 mg kg
-1 h
-1
ketamine. Mechanical ventilation was provided by pres-
sure-controlled ventilation with a Servo 900 ventilator
(Siemens, Munich, Germany). The ventilation protocol
used a tidal volume of 10 ml/kg body weight and a posi-
tive end expiratory pressure of 3 cm H2O.
Instrumentation
After placement of a 3-lm central venous catheter
(Certofix; Braun, Meslungen, Germany) and an 8.5-F
introducer (Arrow, Erding, Germany) into the right
internal jugular vein, a Swan-Ganz thermodilution
catheter (Edwards Laboratories, Irvine, CA, USA) was
introduced into the pulmonary artery. Next, the right
femoral artery was cannulated with a 4.5-Fr introducer
set (Arrow, Erding, Germany), and a COLD catheter
(Pulsion Medical Systems, Munich, Germany) was
advanced 30 cm to reach the distal aorta. A suprapubic
cystofix catheter (Braun, Melsungen, Germany) was
inserted for measurement of diuresis. To provide ade-
quate fluid replacement, animals received full-electrolyte
solution 10 ml kg
-1 h
-1 i.v. (Jonosteril; Fresenius, Bad
Homburg., Germany) during the study period.
Measurement and calculations
All intravascular catheters were connected to pressure
transducers, and signals were recorded online (PONE-
MAH, St. Paul, MN, USA). Measured variables included
heart rate (HR), mean arterial pressure (MAP), central
venous pressure (CVP), pulmonary artery pressure
(PAP) and pulmonary capillary wedge pressure (PCWP).
Equations for derived variables (e.g., systemic vascular
resistance (SVR), pulmonary vascular resistance (PVR),
systemic oxygen delivery (DO2l)) were as described pre-
viously [24,25]. Cardiac output was determined by ther-
modilution technique (Baxter, Unterschleißheim,
Mutz et al. Critical Care 2010, 14:R189
http://ccforum.com/content/14/5/R189
Page 2 of 11Germany). The mean value of three injections of 10 ml
of ice-cooled saline was considered to estimate actual
cardiac output. Intrathoracic blood volume (ITBV) and
extravascular lung water (EVWL) were determined with
a double-indicator dilution technique using the COLD
catheter.
Bronchoscopy
At the described time points, bronchoscopy was per-
formed by identifying the left lobe of the lung with a
standard bronchoscope. Bronchoalveolar lavage was per-
formed using 10 ml of normal saline. The solution was
then centrifuged, and the supernatant was obtained for
further analysis.
Endotoxin Infusion and Experimental Protocol
Escherichia coli 055:B5 lipopolysaccharide (Sigma Che-
micals, Munich, Germany) was infused at a concentra-
tion of 50 μgk g
-1 for 2 hours. Animals were divided
into four groups: (1) no LPS infusion, (2) LPS infusion +
vehicle treatment, (3) LPS infusion + netrin-1 i.v. (1 mg
over 2 hours) and (4) LPS infusion + netrin-1 inh.
(1 mg over 2 hours). For further details about the
experimental protocol, see Figure 1.
BAL myeloperoxidase activity and protein content
BAL supernatant was used for protein measurements
performed according to standard methods. Pulmonary
Table 1 Systemic hemodynamic measurements and
pulmonary hemodynamic measurements
Parameter Group Time
0h 4h 6h
Weight (kg) Control 30.4 ± 0.69
LPS +
Vehicle
31.0 ± 0.58
LPS + Netrin
i.v.
30.2 ± 0.20
LPS + Netrin
inh.
29.8 ± 0.49
CI (ml min
-1 kg
-1) Control 166 ± 3.0 167 ± 5.1 156 ± 10.4
LPS +
Vehicle
170 ± 5.1 136 ± 10.5 122 ± 7.3*
LPS + Netrin
i.v.
163 ± 9.2 128 ± 11.9 114 ± 9.4*
LPS + Netrin
inh
160 ± 3.4 130 ± 11.9 118 ± 8.4*
MAP (mmHg) Control 68 ± 3.7 77 ± 4.9 84 ± 3.7
LPS +
Vehicle
75 ± 6.0 89 ± 3.2 119 ± 6.4*
LPS + Netrin
i.v.
78 ± 6.5 97 ± 6.9* 124 ± 7.0*
LPS + Netrin
inh.
86 ± 6.7 93 ± 2.7 118 ± 4.5*
MPAP (mmHg) Control 16 ± 1.4 17 ± 1.4 17 ± 1.8
LPS +
Vehicle
17 ± 0.7 31 ± 1.8* 31 ± 2.0*
LPS + Netrin
i.v.
18 ± 0.8 31 ± 2.0* 34 ± 2.3*
LPS + Netrin
inh
16 ± 0.5 28 ± 2.5* 31 ± 3.3*
SVR (dyne*s*cm5
kg
-1)
Control 34 ± 1.6 39 ± 3.7 47 ± 5.6
LPS +
Vehicle
36 ± 3.6 54 ± 3.8 80 ± 8.1*
LPS + Netrin
i.v.
41 ± 4.6 66 ± 7.8* 95 ± 11.4*
LPS + Netrin
inh
47 ± 4.2 64 ± 6.2* 88 ± 7.0*
PVR (dyne*s*cm5
kg
-1)
Control 6.5 ± 0.6 6.7 ± 0.4 7.2 ± 0.7
LPS +
Vehicle
6.6 ± 0.4 16.6 ± 2.3* 16.9 ± 1.4*
LPS + Netrin
i.v.
7.1 ± 0.5 16.6 ± 2.4* 20.6 ± 3.0*
LPS + Netrin
inh.
6.8 ± 0.4 15.5 ± 2.8* 18.9 ± 2.1*
PCWP (mmHg) Control 3.9 ± 0.4 3.9 ± 0.5 4.0 ± 0.5
LPS +
Vehicle
3.2 ± 0.6 5.1 ± 0.9 6.6 ± 1.9*
LPS + Netrin
i.v.
4.4 ± 0.3 7.0 ± 0.5* 8.0 ± 0.5*
Table 1 Systemic hemodynamic measurements and pul-
monary hemodynamic measurements (Continued)
LPS + Netrin
inh
4.4 ± 0.5 6.8 ± 0.5* 7.6 ± 0.5*
ITBVI (ml kg
-1) Control 33.3 ± 1.5 33.0 ± 0.7 30.8 ± 1.6
LPS +
Vehicle
31.9 ± 1.8 28.0 ± 1.3 32.0 ± 3.0
LPS + Netrin
i.v.
34.4 ± 3.1 31.9 ± 2.0 35.5 ± 2.1
LPS + Netrin
inh.
32.1 ± 1.3 29.0 ± 0.8 33.0 ± 0.6
EVLWI (ml kg
-1) Control 5.5 ± 0.4 6.0 ± 0.6 6.5 ± 0.5
LPS +
Vehicle
5.7 ± 0.7 9.1 ± 2.1 9.7 ± 1.3*
LPS + Netrin
i.v.
5.1 ± 0.7 7.5 ± 0.4 11.9 ± 1.4*
LPS + Netrin
inh.
4.8 ± 0.4 6.3 ± 0.7 8.1 ± 1.3*
Measurements are compared in the control, vehicle and netrin-1 treatment
groups 4 hours and 6 hours after the end of treatment (data are means ±
SEM and indexed in body weight; P < 0.05; *versus control group). Cardiac
index (CI), mean arterial pressure (MAP), mean pulmonary arterial pressure
(MPAP), systemic vascular resistance index (SVR), pulmonary vascular
resistance index (PVR), pulmonary capillary wedge pressure (PCWP), central
venous pressure (CVP), intrathoracic blood volume index (ITBVI), extravascular
lung water index (EVLWI).
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a s s a yf o rt h ea z u r o p h i l i cn e u t r o p h i lg r a n u l ep r o t e i n
myeloperoxidase (MPO) as described previously [26].
Histopathological evaluation of ALI
After animals were killed, lung tissue was excised from
the right lower lobe of the lung and fixed in 10% for-
maldehyde solution. Tissues were then embedded in
paraffin and stained with hematoxylin and eosin. Three
random tissue sections from four different lungs in each
group were examined.
Application of Netrin-1
Inhaled netrin-1 (1 mg) was dissolved in 20 ml of NaCl
0.9% and applied through Venta-neb-ir (NEBU TEC,
Elsenfeld, Germany) over a period of 2 hours. Intrave-
nous netrin-1 (1 mg) was dissolved and applied with a
standard infusion pump through a central venous cathe-
ter. Vehicle control was performed using porcine serum
albumin (1 mg; Sigma Chemicals, Munich, Germany)
dissolved in 20 ml of NaCl 0.9% and applied nebulized
and intravenously simultaneously. Calculation of netrin-
1d o s er e s u l t e df r o me x p e r i m ents previously performed
in mice [20] and was calculated according to porcine
weight. Given the fact that netrin i.v. and netrin inh.
were equally efficient in our murine model, we also
used an equal dose of netrin-1 i.v. and netrin-1 inh. in
this porcine model.
Measurement of BAL cytokine concentration
Cytokine concentration was measured in supernatant of
BAL and in serum of animals with standard enzyme-
linked immunosorbent assay kits (R&D Systems,
Minneapolis, MN, USA).
Computer tomography
At the end of the study protocol, animals were killed
and transported immediately to a standard spiral com-
puter tomographer (Siemens, Munich, Germany). Ani-
mals were then scanned using standard protocol for
evaluation of radiographic signs of lung injury.
Statistical analysis
Data are given as means ± standard error of the mean.
Statistical analysis was carried out using the JMP soft-
ware package (SAS, Cary, NC, USA). Values were ana-
lyzed by Mann-Whitney U test for independent groups,
since normal distribution of samples was not assumed
(SigmaStat 3.10; Systat Software, San Jose, CA, USA).
Statistical significance was assumed at P < 0.05.
Figure 1 Experimental protocol. Control animals received mechanical ventilation only. Acute lung injury (ALI) was induced through
lipoploysaccharide (LPS) infusion (50 μg/kg over 2 h), and subsequently animals were treated with either vehicle (50 ml of NaCl 0.9% + 1 mg of
bovine serum albumin), netrin-1 i.v. (1 mg i.v. in 50 ml of NaCl 0.9%) or netrin-1 inh. (1 mg in 50 ml of NaCl 0.9%) for 2 hours. Following this, the
observation period was 6 hours until the end of the experimental protocol. Hemodynamic measurements, serum levels of cytokines and
bronchoalveolar lavage (BAL) were determined as indicated.
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Hemodynamic measurements do not differ between
intervention groups
Following the experimental protocol (Figure 1), we per-
formed systemic hemodynamics, pulmonary hemody-
namics and other variables to evaluate whether we
could determine a significant difference between groups.
We found a significant increase of systemic vascular
resistance, mean arterial pressure, pulmonary vascular
resistance, mean pulmonary pressure, pulmonary capil-
lary wedge pressure and cardiac index in animals follow-
ing LPS infusion, which was performed as described
previously [27]. However, we did not find a significant
difference between the vehicle, the netrin-1 i.v. or
netrin-1 inh. groups (Table 1).
Evaluation of pulmonary injury
To identify the role of LPS infusion on pulmonary oxy-
genation and ventilation, we evaluated variables deter-
mining changes in respiration, oxygenation and
ventilation. We found decreased static compliance and
an increase in inspiratory pressure after LPS exposure.
Furthermore, we found that animals treated with netrin-
1 had a tendency for an improved oxygenation index
compared to animals in the vehicle group (vehicle, 158
± 30; netrin-1 i.v., 204 ± 31; netrin-1 inh., 217 ± 20; P =
0.09) (Table 2).
Animals treated with netrin-1 demonstrate reduced
radiological signs of ALI
Initially, we evaluated whether the animals treated with
netrin-1 would demonstrate reduced radiological signs
of pulmonary injury after 6 hours compared to vehicle
controls. For this purpose, we performed standard spiral
chest computed tomography (CT) and evaluated pul-
monary injury at the level of the bronchi just below the
tracheal bifurcation and at the basal level just above the
diaphragm. We found reduced signs of pulmonary
edema, patchy infiltrates and inflammatory changes in
the animals treated with netrin-1 i.v. or netrin-1 inh. as
compared to vehicle controls (Figure 2). Control animals
receiving mechanical ventilation only did not demon-
strate significant pulmonary changes.
Intravenous netrin-1 dampens systemic inflammatory
cytokines
To identify whether netrin-1 administration would result
in a significant reduction of systemic inflammation, we
evaluated levels of serum TNF-a and interleukin-6. For
this purpose, we obtained blood samples at the termina-
tion of LPS infusion, 1 hour after the initiation of
Table 2 Variables determining respiration, oxygenation
and ventilation in vehicle controls and netrin-1-treated
animals
Parameter Group Time
0h 4h 6h
PaO2/FiO2
(mmHg)
Control 483 ± 31 513 ± 48 493 ± 77
LPS + Vehicle 453 ± 10 255 ± 38* 158 ± 30*
LPS + Netrin
i.v.
491 ± 31 254 ± 18* 204 ± 31*
LPS + Netrin
inh
487 ± 6 272 ± 11* 217 ± 20*
PaCO2 (kPa) Control 5.2 ± 0.2 5.1 ± 0.2 4.8 ± 0.1
LPS + Vehicle 5.0 ± 0.1 5.1 ± 0.2 5.4 ± 0.3
LPS + Netrin
i.v.
5.3 ± 0.4 5.1 ± 0.2 5.2 ± 0.7
LPS + Netrin
inh.
5.0 ± 0.2 4.6 ± 0.1 5.2 ± 0.3
DO2 (ml min
-1
kg
-1)
Control 1207 ± 60 1139 ± 49 940 ± 88
LPS + Vehicle 1132 ± 61 1132 ± 97 1009 ± 28
LPS + Netrin
i.v.
1207 ± 83 1139 ± 97 960 ± 69
LPS + Netrin
inh
1102 ± 38 1147 ± 120 997 ± 84
Ppeak (mbar) Control 14.4 ± 0.4 14.5 ± 0.4 14.7 ± 0.8
LPS + Vehicle 14.4 ± 0.5 20.8 ± 2.1* 22.7 ± 3.0*
LPS + Netrin
i.v.
14.4 ± 1.0 18.9 ± 1.4* 19.8 ± 1.8*
LPS + Netrin
inh
14.2 ± 0.4 19.2 ± 0.2* 20.7 ± 0.7*
Pmean (mbar) Control 8.1 ± 0.5 8.2 ± 0.5 8.4 ± 0.7
LPS + Vehicle 7.7 ± 0.2 10.3 ± 1.2 11.5 ± 1.8
LPS + Netrin
i.v.
7.4 ± 0.2 9.3 ± 0.3 9.3 ± 0.3
LPS + Netrin
inh.
7.6 ± 0.2 9.3 ± 0.1 10.1 ± 0.3
Compl.st. (ml
cm H2O
-1)
Control 28.3 ± 1.2 29.4 ± 1.0 29.5 ± 1.2
LPS + Vehicle 28.6 ± 0.7 19.3 ± 1.6* 18.2 ± 1.7*
LPS + Netrin
i.v.
28.4 ± 2.0 19.9 ± 1.4* 19.3 ± 1.7*
LPS + Netrin
inh
27.7 ± 1.4 19.1 ± 0.7* 17.7 ± 0.7*
Measurements determining the oxygenation and ventilation in control
animals, in vehicle animals and animals subjected to netrin-1 4 hours and 6
hours after the end of treatment (data are means ± SEM and indexed in body
weight; P < 0.05; *versus control group). Horovitz Index (OI), inspiratory
oxygen fraction (FiO2), carbon dioxide partial pressure (PaCO2), systemic
oxygen delivery (DO2), peak airway pressure (Pinsp), mean airway pressure
(Pmean), static compliance (Compl.st.), respiratory frequency (RF).
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1 administration. We found a significant reduction of
serum TNF-a 1 hour after administration of netrin-1 i.
v. When determining the levels of interleukin-6, we
found a consistent reduction of interleukin-6 at 1, 4 and
6 hours in the netrin-1 i.v. group compared to the vehi-
cle group (Figure 3). No significant effect was observed
in the netrin-1 inh. group.
Netrin-1 reduces alveolar cytokine levels
To identify whether the anti-inflammatory effect of
netrin-1 would influence the inflammatory process in the
alveolar compartment of the lung, we performed bronch-
oalveolar lavage and determined the levels of inflamma-
tory cytokines within this lavage. We found significant
reduced levels of TNF-a (vehicle, 633 ± 172 pg ml
-1;
n e t r i n - 1i . v . ,8 4±5p gm l
-1;n e t r i n - 1i n h . ,1 6 8±7 4p g
ml
-1; both P < 0.05), interleukin-1b (vehicle, 713 ± 280
pg ml
-1; netrin-1 i.v., 108 ± 5 pg ml
-1; netrin-1 inh., 164 ±
18 pg ml
-1; both P < 0.05) and interleukin-6 (vehicle, 906
± 207 pg ml
-1; netrin-1 i.v., 269 ± 31 pg ml
-1;n e t r i n - 1
inh., 399 ± 101 pg ml
-1; both P < 0.05) in the BAL of the
animals treated with netrin-1 compared to the vehicle
group (Figures 4a-c). When determining the concentra-
tion of interleukin-8 within the BAL, we found a signifi-
cant reduction in the netrin-1 i.v. group and a trend
toward a reduction in the netrin-1 inh. group (Figure 4d).
Netrin-1 reduces protein content, MPO activity and
histopathological signs of ALI
Next, we proceeded to investigate whether netrin-1
influences the content of protein within the alveolar
space and the leukocyte activity measured through the
activity of MPO. Netrin-1 i.v. and netrin-1 inh. reduced
the protein content and MPO activity within the alveo-
lar space (Figures 5a and 5b). This was reflected in the
histopathological sections, demonstrating reduced histo-
logical signs of inflammation in the netrin-1 treatment
groups (Figure 5c).
Discussion
We report here that the neuronal guidance protein
netrin-1 significantly dampens the degree of intra-
alveolar inflammation in a porcine model of lung injury.
Netrin-1 administration resulted in a reduction of intra-
alveolar MPO activity, reduced alveolar protein content
and improved histological appearance of pulmonary tis-
sue. Furthermore, we found that netrin-1 administration
reduced the concentration of inflammatory cytokines
within the alveolar space. As such, netrin-1 dampened a
crucial component of lung injury, since pulmonary
inflammation is the major contributor to the pathologi-
cal derangement of ALI.
The initial stages of ALI are marked by the infiltration
of neutrophils from the vascular into the alveolar space,
which becomes the site of a profound inflammation
[28]. Proinflammatory cytokines such as TNF-a or
interleukin-8 foster this intra-alveolar inflammation,
which might subsequently become self-propagating and
persist long after the initial pulmonary insult is resolved.
The clinical prognosis of ALI correlates with the extent
of this intra-alveolar inflammation [14,15]. This is
underscored by the fact that the concentration of
inflammatory cytokines is reduced in patients surviving
ARDS compared to nonsurvivors [29]. Current therapy
strategies are aimed to achieve control of this
Figure 2 Netrin-1 dampens radiographic signs of ALI. Chest computed tomography was performed in animals after mechanical ventilation
(control) 6 hours following treatment with vehicle, netrin-1 i.v. or netrin-1 inh. Pictures demonstrate one representative animal per group (n =4
per group).
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Page 6 of 11Figure 4 Netrin-1 dampens pulmonary cytokine release. (a) TNF-a levels in bronchoalveolar lavage (BAL) of control animals, animals treated
with vehicle netrin-1 i.v. or netrin-1 inh. (b) Concentration of interleukin-1b in the BAL. (c) Concentration of interleukin-6 in the BAL. (d)
Concentration of interleukin-8 in the BAL prior to treatment and 6 hours following treatment with vehicle, netrin-1 i.v. or netrin-1 inh. (data are
means ± SEM; *P < 0.05 as indicated, n = 5-6 per group).
Figure 3 Netrin-1 dampens systemic inflammation. (a) Serum tumor necrosis factor (TNF)-a levels and (b) serum interleukin (IL)-6 levels in
controls prior to treatment and 6 hours following treatment with vehicle, netrin-1 i.v. or netrin-1 inh. (data are means ± SEM; *P < 0.05 as
indicated, n = 5-6 per group).
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or the modification of mechanical ventilation [30,31]. In
this study, we attempted a novel approach for anti-
inflammatory control and used the neuronal guidance
p r o t e i nn e t r i n - 1i nal a r g ea n i m a lm o d e l .A ss u c h ,w e
moved from a murine wild-type and knockout model,
which focused on the mechanisms underlying the anti-
inflammatory properties of netrin-1, toward the porcine
LPS-induced ALI model that more closely resembles the
human pathobiology. We were able to confirm in this
model the potential of netrin-1 to reduce intra-alveolar
inflammation, which was associated with a tendency of
netrin-1 to improve oxygenation. Furthermore, alveolar
cytokine levels were significantly reduced through
netrin-1 treatment. Therefore, our findings demonstrate
that a significant reduction of the inflammatory changes
of ALI is possible though the neuronal guidance protein
netrin-1 and confirm our previous findings in mice [20].
Only recently neuronal guidance proteins have been
discovered to hold anti-inflammatory potential
[18,19,26]. The guidance protein netrin-1 serves as a
stop signal during axonal growth in the CNS [32,33].
Subsequent work has demonstrated the expression of
netrin-1 outside the CNS and the importance of netrin-
1 for neutrophil migration [19]. Netrin-1 is expressed in
large quantities in the endothelium, where it induces
angiogenesis and controls the trafficking of leukocytes
from the vascular space [19,34]. Furthermore, netrin-1
possesses anti-inflammatory and tissue-protective poten-
tial during renal and myocardial ischemia-reperfusion
(IR) injury [35,36]. Netrin-1 is also expressed in signifi-
cant amounts by epithelial cells on mucosal surfaces
such as the intestine and the lung [26]. We have
demonstrated previously that pulmonary netrin-1
expression is reduced during inflammatory or mechani-
cal lung injury and that substitution with exogenous
netrin-1 results in reduced pulmonary inflammation
through the A2BAR. In this study, we attempted to
further these findings one step closer to clinical applica-
tion and administered netrin-1 i.v. or netrin-1 inh. in a
porcine model. We found in this study that the netrin-1
i.v. application possesses greater anti-inflammatory
Figure 5 Netrin-1 dampens myeloperoxidase activity and histopathological signs of pulmonary inflammation. (a) Myeloperoxidase
activity in the BAL of control animals, animals treated with vehicle after LPS infusion and animals treated with either netrin-1 i.v. or netrin-1 inh.
(b) Protein content in the BAL of experimental animals. (c) Histology sections of controls and 6 hours following treatment with vehicle, netrin-1
i.v. or netrin-1 inh. (data are means ± SEM; *P < 0.05 as indicated, n = 5-6 per group, histology sections are from one representative animal per
group).
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surprising to us, given that we previously found an
equal potential of intravenous and inhaled netrin-1
administration to reduce pulmonary inflammation in
our murine study. This finding is likely explained by the
fact that netrin-1 i.v. is more efficient owing to the safe
and controlled administration of netrin-1 via intrave-
nous infusion compared to the netrin-1 inh. application
that carries the limitations of nebulized drug administra-
tion during mechanical ventilation. No drugs are cur-
rently available to induce netrin-1 selectively, but this
could be the focus of future research and would avoid
the administration of the expensive recombinant
protein.
Several other limitations of the presented study have
to be outlined. First, we did not confirm the reduction
of netrin-1 within pulmonary tissue, since the netrin-1
sequence in the porcine species used is not available.
Given the fact that both Ly et al. [19] and Mirakaj et al.
[20] demonstrated a reduction of netrin-1 within pul-
monary tissue during lung injury, it has to be considered
likely that a repression of netrin-1 might also be present
in this model of ALI. Second, we did not demonstrate a
survival benefit in the study group receiving netrin-1
treatment compared to the vehicle group. Several stu-
dies have used porcine models of ALI to report impor-
tant novel findings, yet have not reported the associated
mortality benefit of their intervention [37,38]. During a
potential long-term ventilation model, repeated adminis-
tration of netrin-1 would be necessary to prove a benefit
of netrin-1 for survival. Given the extremely high cost of
such an intervention at the moment, future well-funded
studies will be necessary to answer this question. Finally,
the small number of animals used has to be seen as a
limitation of this study. The primary focus of this study,
however, was to highlight a novel approach for the con-
trol of intra-alveolar inflammation through a neuronal
guidance protein in a large animal model, and this is
described in this study for the first time. The tendency
for improved oxygenation in both netrin-1 groups is
most likely a reflection of this reduced intra-alveolar
inflammation, as we also found a significant reduction
of intra-alveolar cytokine levels and improved histology
in these groups. Therefore, on the basis of our data,
although limited through the number of animals stu-
died, we propose to pursue this novel substance as a
potential future therapeutic agent for conditions asso-
ciated with lung injury.
Taken together, the present study implicates a novel
approach for the control of pulmonary inflammation
during the initial stages of ALI. Additional studies are
needed to further explore the therapeutic potential of
netrin-1 during acute inflammatory changes in the lung,
thereby leading the way to a possible translation from
animal studies toward novel therapies for ALI in
humans.
Conclusions
In this study, we addressed our recent finding of the
anti-inflammatory role of netrin-1 and used inhaled or
intravenous netrin-1 to reduce intra-alveolar inflamma-
tion during ALI in a porcine model. ALI is marked by a
self-propagating inflammation within the alveolar space
that results in the loss of pulmonary function. Thera-
peutic strategies are aimed at reducing this inflamma-
tory process. We present here evidence that the
application of netrin-1 results in reduced leukocyte
activity within the alveolar space, dampens the release of
cytokines and improves the histolopathological changes
of pulmonary tissue in animals exposed to netrin-1.
This study therefore brings one step forward the only
recently discovered anti-inflammatory function of
netrin-1 to a potential therapeutic translation and appli-
cation for the treatment of ALI.
Key messages
￿ Inhaled netrin-1 dampens the extent of intra-alveo-
lar inflammation during ALI.
￿ Intravenous application of netrin-1 additionally
possesses the potential to reduce systemic inflamma-
tion measured as serum cytokine concentration dur-
ing ALI.
￿ The histological and radiological pathology of ALI
are attenuated through netrin-1.
￿ To the best of our knowledge, this study is the first
to report the potential of recombinant netrin-1 in a
large animal model and enables a possible transla-
tion of the research findings from mice to humans.
Abbreviations
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; BAL:
bronchoalveolar lavage; CNS: central nervous system; CT: computed
tomography; CVP: central venous pressure; DO2l: systemic oxygen delivery;
EVWL: extravascular lung water; H&E: hematoxylin and eosin; HR: heart rate;
IL: interleukin; inh., inhaled; ITBV: intrathoracic blood volume; i.v.: intravenous;
MAP: mean arterial pressure; LPS: lipopolysaccharide; MPO: myeloperoxidase;
PCWP: pulmonary capillary wedge pressure; PAP: pulmonary artery pressure;
PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; TNF:
tumor necrosis factor.
Acknowledgements
We thank Alice Mager for technical assistance with enzyme-linked
immunosorbent assay measurements and for histology sections. We also
thank Professor. B. Vollmar (Institute for Experimental Surgery University of
Rostock) for support in animal experiments and Professor K. Hauenstein and
his team (Department of Diagnostic Radiology University of Rostock) for CT
scans. This work was supported by a Fortüne University of Tuebingen Grant
(Fortüne Grant 1778-0-0), a grant from the European Society of
Anesthesiology (ESA Research Grant) to VM, and Deutsche
Forschungsgemeinschaft (DFG) grant DFG-RO 3671/4-1 to PR.
Mutz et al. Critical Care 2010, 14:R189
http://ccforum.com/content/14/5/R189
Page 9 of 11Author details
1Department of Anesthesiology and Intensive Care Medicine, University
Hospital Rostock, Rostock University, Schillingallee 35, Rostock 18057,
Germany.
2Department of Anesthesiology and Intensive Care Medicine,
University Hospital Tübingen, Eberhard-Karls University, Hoppe Seyler Strasse
3, Tübingen 72076, Germany.
3Clinic of Anesthesiology, Intensive Care
Medicine and Pain Therapy, University Hospital Frankfurt am Main, Goethe
University, Theodor Stern Kai 7, Frankfurt am Main 60590, Germany.
Authors’ contributions
The hypothesis was developed by PR and VM; animal experiments were
performed by CM, PW, and KW; and in vitro analysis was performed by KK
and VM. The manuscript was written and edited by DAV, TI, GNS and PR.
Competing interests
The authors declare that they have no competing interests.
Received: 22 April 2010 Revised: 7 August 2010
Accepted: 22 October 2010 Published: 22 October 2010
References
1. Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG,
Bonde J: Incidence and mortality after acute respiratory failure and acute
respiratory distress syndrome in Sweden, Denmark, and Iceland. The
ARF Study Group. Am J Respir Crit Care Med 1999, 159:1849-1861.
2. Ware LB, Matthay MA: The Acute Respiratory Distress Syndrome. N Engl J
Med 2000, 342:1334-1349.
3. Reutershan J, Ley K: Bench-to-bedside review: acute respiratory distress
syndrome: how neutrophils migrate into the lung. Crit Care 2004,
8:453-461.
4. Reutershan J, Morris MA, Burcin TL, Smith DF, Chang D, Saprito MS, Ley K:
Critical role of endothelial CXCR2 in LPS-induced neutrophil migration
into the lung. J Clin Invest 2006, 116:695-702.
5. Abraham E, Carmody A, Shenkar R, Arcaroli J: Neutrophils as early
immunologic effectors in hemorrhage- or endotoxemia-induced acute
lung injury. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1137-L1145.
6. Azoulay E, Darmon M, Delclaux C, Fieux F, Bornstain C, Moreau D,
Attalah H, Le Gall JR, Schlemmer B: Deterioration of previous acute lung
injury during neutropenia recovery. Crit Care Med 2002, 30:781-786.
7. Ranieri VM, Giunta F, Suter PM, Slutsky AS: Mechanical ventilation as a
mediator of multisystem organ failure in acute respiratory distress
syndrome. JAMA 2000, 284:43-44.
8. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M,
Bernard GR, Wheeler AP: Lower tidal volume ventilation and plasma
cytokine markers of inflammation in patients with acute lung injury. Crit
Care Med 2005, 33:1-6, discussion 230-232.
9. Eckle T, Grenz A, Laucher S, Eltzschig HK: A2B adenosine receptor
signaling attenuates acute lung injury by enhancing alveolar fluid
clearance in mice. J Clin Invest 2008, 118:3301-3315.
10. Reutershan J, Cagnina RE, Chang D, Linden J, Ley K: Therapeutic anti-
inflammatory effects of myeloid cell adenosine receptor A2a stimulation
in lipopolysaccharide-induced lung injury. J Immunol 2007, 179:1254-1263.
11. Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri KC, Eltzschig HK:
Adenosine and inflammation: CD39 and CD73 are critical mediators in
LPS-induced PMN trafficking into the lungs. FASEB J 2009, 23:473-482.
12. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M,
Schoenfeld D, Thompson BT: Higher versus lower positive end-expiratory
pressures in patients with the acute respiratory distress syndrome. N
Engl J Med 2004, 351:327-336.
13. Brower RG, Morris A, MacIntyre N, Matthay MA, Hayden D, Thompson T,
Clemmer T, Lanken PN, Schoenfeld D: Effects of recruitment maneuvers in
patients with acute lung injury and acute respiratory distress syndrome
ventilated with high positive end-expiratory pressure. Crit Care Med 2003,
31:2592-2597.
14. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K:
Persistent elevation of inflammatory cytokines predicts a poor outcome
in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient
predictors of outcome over time. Chest 1995, 107:1062-1073.
15. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A:
Inflammatory cytokines in the BAL of patients with ARDS. Persistent
elevation over time predicts poor outcome. Chest 1995, 108:1303-1314.
16. Kennedy TE, Serafini T, de la Torre JR, Tessier-Lavigne M: Netrins are
diffusible chemotropic factors for commissural axons in the embryonic
spinal cord. Cell 1994, 78:425-435.
17. Serafini T, Kennedy TE, Galko MJ, Mirzayan C, Jessell TM, Tessier-Lavigne M:
The netrins define a family of axon outgrowth-promoting proteins
homologous to C. elegans UNC-6. Cell 1994, 78:409-424.
18. Wu JY, Feng L, Park HT, Havlioglu N, Wen L, Tang H, Bacon KB, Jiang Z,
Zhang X, Rao Y: The neuronal repellent Slit inhibits leukocyte chemotaxis
induced by chemotactic factors. Nature 2001, 410:948-952.
19. Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan P, Moore KJ, Kinane TB:
Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc Natl Acad
Sci USA 2005, 102:14729-14734.
20. Mirakaj V, Thix CA, Laucher S, Mielke C, Morote-Garcia JC, Schmit MA,
Henes J, Unertl KE, Kohler D, Rosenberger P: Netrin-1 dampens pulmonary
inflammation during acute lung injury. Am J Respir Crit Care Med 2010,
181:815-824.
21. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-
Garcia JC, Unertl K, Eltzschig HK: Hypoxia-inducible factor-dependent
induction of netrin-1 dampens inflammation caused by hypoxia. Nat
Immunol 2009, 10:195-202.
22. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP: HIF-dependent
induction of adenosine A2B receptor in hypoxia. FASEB J 2006,
20:2242-2250.
23. Schingnitz U, Hartmann K, Macmanus CF, Eckle T, Zug S, Colgan SP,
Eltzschig HK: Signaling through the A2B adenosine receptor dampens
endotoxin-induced acute lung injury. J Immunol 2010, 184:5271-5279.
24. Vagts DA, Iber T, Puccini M, Szabo B, Haberstroh J, Villinger F, Geiger K,
Noldge-Schomburg GF: The effects of thoracic epidural anesthesia on
hepatic perfusion and oxygenation in healthy pigs during general
anesthesia and surgical stress. Anesth Analg 2003, 97:1824-1832.
25. Vagts DA, Iber T, Szabo B, Haberstroh J, Reising K, Puccini M, Geiger K,
Noldge-Schomburg GF: Effects of epidural anaesthesia on intestinal
oxygenation in pigs. Br J Anaesth 2003, 90:212-220.
26. Henes J, Schmit MA, Morote-Garcia JC, Mirakaj V, Kohler D, Glover L, Eldh T,
Walter U, Karhausen J, Colgan SP, Rosenberger P: Inflammation-associated
repression of vasodilator-stimulated phosphoprotein (VASP) reduces
alveolar-capillary barrier function during acute lung injury. FASEB J 2009,
23:4244-4255.
27. Rosenthal C, Caronia C, Quinn C, Lugo N, Sagy M: A comparison among
animal models of acute lung injury. Crit Care Med 1998, 26:912-916.
28. Anderson WR, Thielen K: Correlative study of adult respiratory distress
syndrome by light, scanning, and transmission electron microscopy.
Ultrastruct Pathol 1992, 16:615-628.
29. Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM, Gadek JE:
Lung neutrophils in the adult respiratory distress syndrome: clinical and
pathophysiologic significance. Am Rev Respir Dis 1986, 133:218-225.
30. Amato MB, Carvalho CR, Isola A, Vieira S, Rotman V, Moock M, Jose A,
Franca S: Mechanical ventilation in Acute Lung Injury (ALI)/Acute
Respiratory Discomfort Syndrome (ARDS). J Bras Pneumol 2007, 33(Suppl
2S):S119-127.
31. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-
Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY,
Carvalho CR: Effect of a protective-ventilation strategy on mortality in
the acute respiratory distress syndrome. N Engl J Med 1998, 338:347-354.
32. Serafini T, Colamarino SA, Leonardo ED, Wang H, Beddington R,
Skarnes WC, Tessier-Lavigne M: Netrin-1 is required for commissural axon
guidance in the developing vertebrate nervous system. Cell 1996,
87:1001-1014.
33. Colamarino SA, Tessier-Lavigne M: The axonal chemoattractant netrin-1 is
also a chemorepellent for trochlear motor axons. Cell 1995, 81:621-629.
34. Park KW, Crouse D, Lee M, Karnik SK, Sorensen LK, Murphy KJ, Kuo CJ, Li DY:
The axonal attractant netrin-1 is an angiogenic factor. Proc Natl Acad Sci
USA 2004, 101:16210-16215.
35. Wang W, Reeves WB, Ramesh G: Netrin-1 and kidney injury. I. Netrin-1
protects against ischemia-reperfusion injury of the kidney. Am J Physiol
Renal Physiol 2008, 294:F739-F747.
36. Zhang J, Cai H: Netrin-1 prevents ischemia/reperfusion-induced
myocardial infarction via a DCC/ERK1/2/eNOS(s1177)/NO/DCC feed-
forward mechanism. J Mol Cell Cardiol 2010, 48:1060-1070.
37. Grasso S, Stripoli T, Sacchi M, Trerotoli P, Staffieri F, Franchini D, De
Monte V, Valentini V, Pugliese P, Crovace A, Driessen B, Fiore T:
Mutz et al. Critical Care 2010, 14:R189
http://ccforum.com/content/14/5/R189
Page 10 of 11Inhomogeneity of lung parenchyma during the open lung strategy: a
computed tomography scan study. Am J Respir Crit Care Med 2009,
180:415-423.
38. Richard JC, Janier M, Lavenne F, Berthier V, Lebars D, Annat G, Decailliot F,
Guerin C: Effect of position, nitric oxide, and almitrine on lung perfusion
in a porcine model of acute lung injury. J Appl Physiol 2002, 93:2181-2191.
doi:10.1186/cc9301
Cite this article as: Mutz et al.: The neuronal guidance protein netrin-1
reduces alveolar inflammation in a porcine model of acute lung injury.
Critical Care 2010 14:R189.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mutz et al. Critical Care 2010, 14:R189
http://ccforum.com/content/14/5/R189
Page 11 of 11